Primary study · included by 1 review

Gingivitis Effectiveness of Emulgel Containing 2% Resveratrol in Orthodontic Patients: An 8-Week Randomized Clinical Trial.

Golshah 2021 · Golshah Amin, Mirzaeei Shahla, Nikkerdar Nafiseh, et al. · International journal of dentistry · 2021

Included by

Resveratrol as an Adjunct Therapy in Periodontal Disease: A Systematic Review and Meta-Analysis.
Non-Cochrane · intervention · 2026 · cited as Golshah 2021 · Figures 2 to 4; Tables 1 to 3; References 25 to 34, 40 to 44
Outcome this study informsPooled effectEvidenceCertainty
Bleeding index (%)
Adjunctive resveratrol (oral, gel, spray, mouthwash) with non-surgical periodontal therapy or plaque control vs Non-surgical periodontal therapy or plaque control alone, or placebo
MD -8.11 [-9.57, -6.64]3 studiesGRADE not reported
Bleeding index (%)
Adjunctive resveratrol (oral, gel, spray, mouthwash) with non-surgical periodontal therapy or plaque control vs Non-surgical periodontal therapy or plaque control alone, or placebo
MD -8.95 [-10.47, -7.43]3 studiesGRADE not reported
Bleeding index (%)
Adjunctive resveratrol (oral, gel, spray, mouthwash) with non-surgical periodontal therapy or plaque control vs Non-surgical periodontal therapy or plaque control alone, or placebo
MD -7.72 [-9.13, -6.32]4 studiesGRADE not reported
Bleeding index (%)
Adjunctive resveratrol (oral, gel, spray, mouthwash) with non-surgical periodontal therapy or plaque control vs Non-surgical periodontal therapy or plaque control alone, or placebo
MD -6.79 [-9.06, -4.51]3 studiesGRADE not reported
Bleeding index (%)
Adjunctive resveratrol (oral, gel, spray, mouthwash) with non-surgical periodontal therapy or plaque control vs Non-surgical periodontal therapy or plaque control alone, or placebo
MD -6.50 [-8.02, -4.97]3 studiesGRADE not reported
Bleeding index (%)
Adjunctive resveratrol (oral, gel, spray, mouthwash) with non-surgical periodontal therapy or plaque control vs Non-surgical periodontal therapy or plaque control alone, or placebo · Post-treatment time point most comparable across trials
MD -6.82 [-12.12, -1.53]4 studies · 187 participantsLow

1 including review in total.